Advertisement
Organisation › Details
SR Pharma plc (AIM: SPA.L)
SR Pharma plc is a European biopharmaceutical company, listed on AIM. The Company has two operating subsidiaries Atugen AG (www.atugen.com) based in Berlin, Germany and Stanford Rook Ltd based in London, UK. SR Pharma is a leader in RNAi therapeutics, which is a Nobel Prize winning technology that ”silences” genes linked to the onset of disease. The Company has developed novel, chemically modified proprietary siRNA molecules ("AtuRNAi"), which have a number of advantages over conventional siRNA molecules including enhanced stability against nuclease degradation. In addition, the Company has developed a proprietary delivery system ("AtuPLEX"), which increases bioavailability, circulation times and functional intracellular uptake of siRNA molecules. *
Start | 1992-01-01 established | |
End | 2007-04-26 renamed | |
Group | Silence Therapeutics (Group) | |
Today | Silence Therapeutics plc (Nasdaq: SLN) | |
Successor | Silence Therapeutics plc (Nasdaq: SLN) | |
Industry | RNAi drug (RNAi therapeutic) | |
Region | London, Greater London | |
Country | United Kingdom (GB) | |
Street | 103 New Oxford Street, Centre Point, 26th Floor | |
City | WC1A 1DD London | |
Tel | +44-20-7307-1620 | |
Address record changed: 2009-02-27 | ||
Basic data | Employees | n. a. |
* Document for »About Section«: | ||
Record changed: 2023-07-10 |
Advertisement
More documents for Silence Therapeutics (Group)
- [1] Silence Therapeutics plc. (2/5/24). "Press Release: Silence Therapeutics Announces Oversubscribed $120 Million Private Placement". London....
- [2] Silence Therapeutics plc. (1/31/24). "Press Release: Silence Therapeutics to Participate in Fireside Chat at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference". London....
- [3] Silence Therapeutics plc. (2/21/22). "Press Release: Silence Therapeutics Appoints Craig Tooman President and Chief Executive Officer. Mark Rothera Steps Down as President and CEO". London....
- [4] Gubra ApS. (2/10/22). "Press Release: Gubra ApS and Silence Therapeutics plc Collaborate to Develop RNAi Therapies against Novel Liver-directed Targets from Gubra’s streaMLine Platform". Hørsholm....
- [5] Silence Therapeutics plc. (10/15/21). "Press Release: Silence Therapeutics and Hansoh Pharma Announce Collaboration to Develop Therapeutics Leveraging Silence’s mRNAi GOLD™ Platform". London & Shanghai....
- [6] Silence Therapeutics plc. (3/25/20). "Press Release: Silence Therapeutics Announces Collaboration with AstraZeneca to Discover and Develop siRNA Therapeutics for Cardiovascular, Renal, Metabolic and Respiratory Diseases". London....
- [7] Silence Therapeutics plc. (3/25/20). "Press Release: Silence Therapeutics Announces R&D Update". London....
- [8] Silence Therapeutics plc. (8/5/19). "Press Release: Silence Therapeutics Appoints Jørgen Wittendorff as Head of Manufacturing". London....
- [9] Silence Therapeutics plc. (7/18/19). "Press Release: Silence Therapeutics and Mallinckrodt Announce Collaboration to Develop and Commercialize RNAi Therapeutics for Complement-mediated Diseases". London & Staines-upon-Thames....
- [10] Silence Therapeutics plc. (7/18/19). "Press Release: Mallinckrodt to Make an Equity Investment in Silence Therapeutics as Part of a Collaboration". London & Staines-upon-Thames....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top